À propos de cet article

Citez

1. Singh R, Rao HK, Singh TG. Advanced glycated end products (ages) in diabetes and its complications: an insight. Plant Arch. 2020; 20(1): 3838-3841. Search in Google Scholar

2. Sharma VK, Singh TG. Chronic Stress and Diabetes Mellitus: Interwoven Pathologies. Curr Diabetes Rev. 2019;16(6): 546-556.10.2174/1573399815666191111152248 Search in Google Scholar

3. Olokoba AB, Obateru OA, Olokoba LB. Type 2 Diabetes Mellitus: A Review of Current Trends. Oman Med J. 2012; 27(4): 269–273.10.5001/omj.2012.68346475723071876 Search in Google Scholar

4. Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus – present and future perspective. Nat. Rev. Endocrinol. 2011; 8(4):228-36.10.1038/nrendo.2011.183 Search in Google Scholar

5. Singh R, Rao HK, Singh TG. Neuropathic pain in Diabetes Mellitus: Challenges and Future Trends. Obes Med. 2020; 18.100215.10.1016/j.obmed.2020.100215 Search in Google Scholar

6. Jothivel N, Ponnusamy SP, Appachi M. Antidiabetic activities of methanol leaf extract of Costus pictus D. Don in alloxan-induced diabetic rats. J health sci. 2007; 53(6):655-663.10.1248/jhs.53.655 Search in Google Scholar

7. Drucker D, Easley C, Kirkpatrick P. News and analysis. Nat Rev Drug Discov. 2007; 6:109-110.10.1038/nrd224517342863 Search in Google Scholar

8. Singh TG, Sharma R, Kaur A, Dhiman S, Singh R. Evaluation of renoprotective potential of Ficus religiosa in attenuation of diabetic nephropathy in rats. Obes Med. 2020; 19: 100268.10.1016/j.obmed.2020.100268 Search in Google Scholar

9. Al-masri IM, Mohammad MK, Tahaa MO. Inhibition of dipeptidyl peptidase IV (DPP IV) is one of the mechanisms explaining the hypoglycemic effect of berberine. J enzyme inhib med chem. 2009; 24(5):1061–1066.10.1080/1475636080261076119640223 Search in Google Scholar

10. Chinmay D, Deshmukh, Jain A. Diabetes Mellitus: A Review. Int. J. Pure App. Biosci. 2015; 3(3): 224-230. Search in Google Scholar

11. Nathan DM, Buse JB, Davidson MB. Medical management of hyperglycemia in type 2 diabetes: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009; 32:193–203.10.2337/dc08-9025260681318945920 Search in Google Scholar

12. Pratley RE, Gilbert M. Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor agonists and DPP-4 inhibitiors. Rev of Diabet Stud. 2008; 5:73-94.10.1900/RDS.2008.5.73255644518795210 Search in Google Scholar

13. Amori RE, Lau J, Pittas AG. Efficacy and Safety of incretin therapy in type 2 diabetes: Systemic Review and Analysis. JAMA. 2007; 298:194-206.10.1001/jama.298.2.19417622601 Search in Google Scholar

14. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman DE, Khatami H. Efficacy and safety of the Dipeptidyl Peptidase-4 inhibitor Sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2006; 49:2564-71.10.1007/s00125-006-0416-z17001471 Search in Google Scholar

15. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE. Effect of the Dipeptidyl Peptidase-4, inhibitor Sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006; 29:2632-37.10.2337/dc06-070317130196 Search in Google Scholar

16. Cherbonnel B, Karasik A, Liu J, Wu M, Menininger G. Efficacy and safety of the Dipeptidyl Peptidase-4 inhibitor Sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006; 29:2638-43.10.2337/dc06-070617130197 Search in Google Scholar

17. Hermansen K, Kipnes M, Luo E, Fanurik D, Khataami H, Stein P. Efficacy and Safety of the dipeptidyl peptidase-4 inhibitor, Sitagliptin, in patients with type 2 diabetes inadequately controlled on glimepiride alone or on glimepiride and Metformin. Diabetes Obese Metab. 2007; 9:733-45.10.1111/j.1463-1326.2007.00744.x17593236 Search in Google Scholar

18. Sharma VK, Singh TG, Insulin resistance and bioenergetic manifestations: Targets and approaches in Alzheimer’s disease. Life Sci. 2020; 118401.10.1016/j.lfs.2020.11840132926928 Search in Google Scholar

eISSN:
2335-075X
ISSN:
1820-8665
Langue:
Anglais
Périodicité:
4 fois par an
Sujets de la revue:
Medicine, Clinical Medicine, other